Tag Archives: agenus

December, 2018

20 December
Gilead and Agenus Partner for Development of Immuno-Oncology Therapies

FOSTER CITY, Calif. & LEXINGTON, Mass.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies. Under the terms of the agreement, Agenus will receive $150 …
Share

30 December
Agenus Acquires PhosImmune in $44.9 Million Deal

LEXINGTON, Mass.–(BUSINESS WIRE)–Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for cancer, today announced that it has acquired privately-held PhosImmune Inc., a company that has discovered an entirely new portfolio of cancer neoantigens. The acquisition provides Agenus the ability to accelerate the development of new cancer vaccines and other …
Share

9 January
Incyte and Agenus Partner for Development of Immuno-Oncology Products

Incyte and Agenus will partner on immuno-oncology targets in a deal worth up to $410 million. The companies announced today that they have entered into a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocycle Display antibody discovery platform. According to terms of the deal, …
Share